
This report presents a guide to selecting high-quality commercial antibodies against Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) by Western blot, immunoprecipitation and immunofluorescence, using a standardized experimental protocol comparing read-outs in knockout cell lines and isogenic parental controls. This study was funded in part by the ALS-Reproducible Antibody Platform (ALS-RAP), established as a public-private partnership by three prominent ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
Heterogeneous nuclear ribonucleoprotein A1, Helix-destabilizing protein, antibody characterization, Single-strand RNA-binding protein, P09651, Western blot, hnRNP core protein A1, immunofluorescence, antibody validation, immunoprecipitation, hnRNP A1
Heterogeneous nuclear ribonucleoprotein A1, Helix-destabilizing protein, antibody characterization, Single-strand RNA-binding protein, P09651, Western blot, hnRNP core protein A1, immunofluorescence, antibody validation, immunoprecipitation, hnRNP A1
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
